What was the overall market valuation of the Japan infertility market in 2024?

The overall market valuation was $91.59 Million in 2024. Read More

What is the projected market valuation for the Japan infertility market by 2035?

The projected market valuation for 2035 is $345.0 Million. Read More

What is the expected CAGR for the Japan infertility market during the forecast period 2025 - 2035?

The expected CAGR for the Japan infertility market during the forecast period 2025 - 2035 is 12.81%. Read More

Which segment had the highest valuation in the Japan infertility market in 2024?

The Assisted Reproductive Technology segment had the highest valuation at $115.0 Million in 2024. Read More

What are the key players in the Japan infertility market?

Key players include CooperSurgical, Merck KGaA, Ferring Pharmaceuticals, and Vitrolife. Read More

How did the Fertility Clinics segment perform in 2024?

The Fertility Clinics segment performed well, with a valuation of $150.0 Million in 2024. Read More

What was the valuation of the Male Factor Infertility segment in 2024?

The Male Factor Infertility segment had a valuation of $105.0 Million in 2024. Read More

What is the projected growth for the Hormone Therapy segment by 2035?

The Hormone Therapy segment is expected to grow, with a projected valuation of $90.0 Million by 2035. Read More

Which end user segment is anticipated to grow the most by 2035?

The Fertility Clinics segment is anticipated to grow the most, reaching $150.0 Million by 2035. Read More

What are the primary causes of infertility in the Japan market?

Primary causes include Male Factor Infertility, Tubal Factors, and Ovulatory Disorders. Read More

Japan Infertility Market

Japan Infertility Market Research Report: Size, Share, Trend Analysis By Sex (Males, Females, Unexplained), By Diagnosis (Men Diagnostic Tests, Women Diagnostic Tests, General Diagnostic Test), By Drugs (Clomiphene Citrate, Letrozole, Serophene, Hormone Treatment, Others) andBy Technology (Assisted Reproductive Technology, Intrauterine Insemination, Surgery) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

12.81%

2024 Market Size

$ 91.59 Million

2035 Market Size

$ 345 Million

Healthcare ● Updated April 2026 Report ID: MRFR/HC/43842-HCR | Pages: 200 | Author: Nidhi Mandole, Garvit Vyas

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Pharmaceutical, BY Type (USD Million)
  1. 4.1.1 Assisted Reproductive Technology
  2. 4.1.2 Hormone Therapy
  3. 4.1.3 Surgery
  4. 4.1.4 Fertility Preservation
2. 4.2 Pharmaceutical, BY End User (USD Million)
  1. 4.2.1 Hospitals
  2. 4.2.2 Fertility Clinics
  3. 4.2.3 Home Care Settings
3. 4.3 Pharmaceutical, BY Gender (USD Million)
  1. 4.3.1 Female
  2. 4.3.2 Male
4. 4.4 Pharmaceutical, BY Cause of Infertility (USD Million)
  1. 4.4.1 Ovulatory Disorders
  2. 4.4.2 Uterine or Cervical Abnormalities
  3. 4.4.3 Tubal Factors
  4. 4.4.4 Male Factor Infertility
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Pharmaceutical
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 CooperSurgical (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Merck KGaA (DE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Ferring Pharmaceuticals (CH)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Vitrolife (SE)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Irvine Scientific (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Reproductive Health Technologies (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 OvaScience (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Genea Limited (AU)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Eugin Group (ES)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 JAPAN MARKET ANALYSIS BY TYPE
3. 6.3 JAPAN MARKET ANALYSIS BY END USER
4. 6.4 JAPAN MARKET ANALYSIS BY GENDER
5. 6.5 JAPAN MARKET ANALYSIS BY CAUSE OF INFERTILITY
6. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF PHARMACEUTICAL
9. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
10. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
11. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
12. 6.12 PHARMACEUTICAL, BY TYPE, 2024 (% SHARE)
13. 6.13 PHARMACEUTICAL, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 PHARMACEUTICAL, BY END USER, 2024 (% SHARE)
15. 6.15 PHARMACEUTICAL, BY END USER, 2024 TO 2035 (USD Million)
16. 6.16 PHARMACEUTICAL, BY GENDER, 2024 (% SHARE)
17. 6.17 PHARMACEUTICAL, BY GENDER, 2024 TO 2035 (USD Million)
18. 6.18 PHARMACEUTICAL, BY CAUSE OF INFERTILITY, 2024 (% SHARE)
19. 6.19 PHARMACEUTICAL, BY CAUSE OF INFERTILITY, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY END USER, 2025-2035 (USD Million)
  3. 7.2.3 BY GENDER, 2025-2035 (USD Million)
  4. 7.2.4 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

Japan Infertility Market Segmentation

Japan Infertility Market By Type (USD Million, 2025-2035)

Assisted Reproductive Technology
Hormone Therapy
Surgery
Fertility Preservation

Japan Infertility Market By End User (USD Million, 2025-2035)

Hospitals
Fertility Clinics
Home Care Settings

Japan Infertility Market By Gender (USD Million, 2025-2035)

Female
Male

Japan Infertility Market By Cause of Infertility (USD Million, 2025-2035)

Ovulatory Disorders
Uterine or Cervical Abnormalities
Tubal Factors
Male Factor Infertility

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”